Taiko Pharmaceutical Co.,Ltd. Stock

Equities

4574

JP3442200006

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-07-16 am EDT 5-day change 1st Jan Change
464 JPY -2.93% Intraday chart for Taiko Pharmaceutical Co.,Ltd. +3.80% +53.14%
Sales 2022 5.04B 31.75M Sales 2023 6.12B 38.56M Capitalization 15.08B 95.02M
Net income 2022 -4.9B -30.84M Net income 2023 -3.61B -22.75M EV / Sales 2022 3.47 x
Net Debt 2022 304M 1.92M Net cash position 2023 2.23B 14.05M EV / Sales 2023 2.1 x
P/E ratio 2022
-3.51 x
P/E ratio 2023
-3.97 x
Employees 208
Yield 2022 *
-
Yield 2023
-
Free-Float 60.75%
More Fundamentals * Assessed data
Dynamic Chart
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2024 CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2024 CI
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 23-DEC-2023. CI
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2023 CI
Certain Common Shares of Cuorips Inc. are subject to a Lock-Up Agreement Ending on 24-SEP-2023. CI
Kingworld Medicines Subsidiary Buys Shares in Taiko Pharmaceutical MT
Taiko Pharmaceutical Co.,Ltd. Provides Earnings Guidance for the Year Ending December 2023 CI
Cuorips Inc. has completed an IPO in the amount of ¥3.432 billion. CI
Taiko Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kingworld Medicines to Invest 832 Million Yen in Taiko Pharmaceutical MT
Taiko Pharmaceutical to Pay 607 Million Yen Penalty; Shares Down 3% MT
Easing Wholesale Inflation Strengthens Japanese Shares; Orix, Partners Near Government Approval for Japan's First Casino Resort MT
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 2023 CI
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 CI
Taiko Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Year ending December 31, 2022 CI
More news
1 day-2.93%
1 week+3.80%
Current month+11.54%
1 month+16.58%
3 months+29.25%
6 months+58.36%
Current year+53.14%
More quotes
1 week
438.00
Extreme 438
480.00
1 month
387.00
Extreme 387
480.00
Current year
285.00
Extreme 285
480.00
1 year
263.00
Extreme 263
480.00
3 years
263.00
Extreme 263
1 045.00
5 years
263.00
Extreme 263
2 928.00
10 years
263.00
Extreme 263
2 928.00
More quotes
Managers TitleAgeSince
President 68 98-11-30
Chairman 73 77-04-30
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chairman 73 77-04-30
President 68 98-11-30
Director/Board Member 57 20-05-31
More insiders
Date Price Change Volume
24-07-16 464 -2.93% 414 400
24-07-12 478 +4.37% 530,900
24-07-11 458 +3.39% 248,000
24-07-10 443 -0.89% 247,500
24-07-09 447 +3.71% 616,600

Delayed Quote Japan Exchange, July 16, 2024 at 02:00 am EDT

More quotes
TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
More about the company